Business Wire

Avania Acquires MAXIS, Advancing MedTech Leadership in Pre-Clinical, Regulatory Strategy, and Clinical Expertise

Share

Avania, a leading, global medical technology contract research organization (CRO), today announced its acquisition of MAXIS, a prominent medical technology development service provider with expertise in pre-clinical engineering, design validation and verification, regulatory affairs, field clinical services, and trial management. MAXIS has offices in San Jose, California, and Frankfurt am Main, Germany, with additional operational staff across the regions. With MAXIS, the combined organization offers unmatched high-touch strategic and operational expertise that uniquely drive results for medical device innovators and emerging original equipment manufacturers (OEMs).

“This acquisition strengthens our position as the leading MedTech focused CRO, advancing innovative medical technologies from ideation to commercialization, providing a range of highly customizable services in combination with robust global regulatory, clinical, and operational strategies to meet the unique needs of emerging OEMs,” said Sapna Hornyak, president and CEO of Avania. “The addition of MAXIS furthers our strategy and will provide us with enhanced capabilities across a broader customer base as we continue to innovate and grow.”

MAXIS clients will benefit from Avania’s extended international footprint, gaining access to the company’s extensive network in the U.S., EU, and Australia. Additionally, Avania brings enhanced services to the combined companies — including biostatistics, data analytics, and medical writing.

MAXIS’ long-standing commitment to emerging technology companies will be greatly enhanced with Avania’s sophisticated infrastructure and extensive resources,” said Kathleen Marshall, president of MAXIS Medical. “Avania’s understanding of our strategic value in the continuum of medical technology development was compelling and decisive, and we are delighted to be able to continue our mission with the Avania team.”

Avania customers will benefit from an expanded roster of subject matter experts in the global pre-clinical, clinical (in vitro diagnostics, artificial intelligence/machine learning, and Software as Medical Device), and regulatory consulting space. Further, MAXIS bolsters the Avania depth across innovative technologies and multiple therapeutic areas.

About Avania

Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.

About MAXIS

MAXIS is a clinical market development company focused on maximizing the clinical, market and commercial success of innovative medical technologies. MAXIS’ ability to design and implement flexible strategies, paired with its commitment to providing the comprehensive, long-term support make it uniquely suited to emerging medical technology companies. Our vast and varied start-up experience enable us to create and adapt highly tailored, choreographed strategies to bring innovative devices through development to the market.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lindsey Langemeier
SCORR Marketing
+1 402-405-4269
lindsey@scorrmarketing.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nasdaq Congratulates Signifier Medical Technologies for Treating 10,000 Patients With eXciteOSA, a Daytime Therapy for Sleep Apnea29.3.2023 18:24:00 EEST | Press release

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that eXciteOSA, the only FDA-authorized daytime therapy for sleep-disordered breathing, has treated over 10,000 patients since the commercial launch in 2021. Nasdaq recognized this milestone by congratulating Signifier Medical on the Nasdaq Tower in the heart of Times Square, New York. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005432/en/ (Photo: Business Wire) Akhil Tripathi, Signifier’s co-founder and CEO said, “This is a proud moment knowing that our therapy has made a positive impact on the lives of so many patients. It’s been a great team effort among our employees, clinicians, distributors, and most of all, our patients.” Signifier Medical is simplifying the complex standard of care for obstructive sleep apnea with eXciteOSA by tackling a root cause -- empowering patients to restore their ni

Flare gas reduction: Graforce a winner at Petronas Race2Decarbonise for groundbreaking solution29.3.2023 18:00:00 EEST | Press release

Out of more than 500 global solutions, Graforce was recognized at the Petronas Race2Decarbonise with its methane electrolysis technology (plasmalysis) in the category “Gas Flaring Reduction or Elimination.” The competition is aimed at accelerating the development of low-carbon solutions and reducing greenhouse gas emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005084/en/ Gas flaring causes more than 400 million tons of CO2 emissions every year. Graforce’s methane electrolysis technology is a groundbreaking solution that converts flare gas and other hydrocarbons into clean hydrogen and solid carbon. (Photo: Business Wire) Gas flaring results in more than 400 million tons of CO2 emissions every year. Thousands of gas flares at production sites around the globe burn approximately 150 billion cubic meters of natural gas each year, thus wasting a valuable resource. Plasmalysis, on the other hand, converts methane

SRMG launches new venture capital arm, SRMG Ventures, with first investments in regional content studio and immersive platform companies29.3.2023 17:36:00 EEST | Press release

SRMG, a global integrated media group, yesterday announced the launch of its corporate venture capital arm, SRMG Ventures. In line with SRMG’s transformative growth strategy, SRMG Ventures will invest in early-stage companies and technologies within the core target areas: media creators, digital media, media enablers and tools, including generative AI, as well as immersive and interactive entertainment. SRMG Ventures will initially target investments from the seed to Series B stage. SRMG Ventures will enable SRMG to back and empower regional talent and entrepreneurs, acting as a catalyst for further growth of the rapidly evolving media industry in the region. SRMG Ventures will provide SRMG with direct access to innovative technologies, as well as new media talent and content creators, that will continue to enhance SRMG’s own media portfolio and drive forward the future of media. The new corporate venture capital arm will additionally help SRMG penetrate new markets and further diversi

LambdaTest Upgrades its Playwright Automation Testing Experience With the Addition of its AI-Powered Integrated Test Intelligence29.3.2023 17:30:00 EEST | Press release

LambdaTest, an intelligent omnichannel digital experience testing cloud platform, has announced the addition of advanced AI-powered test intelligence features to its Playwright testing cloud offering. With this latest development, LambdaTest will now enable enterprises with deeper insights into their test execution process and help them better streamline their quality assurance process. LambdaTest has been constantly working on enhancing its Playwright automation testing cloud and the test intelligence feature is the latest addition to the list. Over the last quarter, LambdaTest has added features like support for browser extension testing, IP-based Geolocation testing, and Playwright component testing. Customers can soon test on Android real devices using Playwright as well. “Test intelligence is at the core of digital transformation in enterprises. Given Playwright’s increasing usage across the business world, we are excited to provide our customers with a deeper and more intuitive v

Statement by SES S.A.29.3.2023 16:47:00 EEST | Press release

In response to rumours in the market, SES S.A. confirms that the company has engaged in discussions regarding a possible combination with Intelsat. At this stage, there can be no certainty that a transaction would materialise. The Board of SES remains fully committed to acting in the best interest of SES and its shareholders. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom